Fig. 2

Clonal HR pathway gene deactivation impacts neoadjuvant immunotherapy consequences in NSCLC patients. a TMB value distribution between MPR/non-MPR groups. b Correlation between TMB and percentage of viable tumor cells. c Clonal TMB value in two groups. d Correlation between clonal TMB and percentage of viable tumor cells. e Existence of HR pathway genes’ clonal SNV in two groups. The size of the circle was proportional to the mutation number. P values were calculated by Fisher’s exact test on all and SCC samples. f Subclonal SCNA fragment number in two groups. g Correlation between subclonal SCNA fragment number and percentage of viable tumor cells. h Deletion status of 13 HR core pathway genes in MPR/non-MPR groups. P values were calculated by Fisher’s exact test or one-side Wilcoxon rank-sum test. Adenocarcinoma samples were marked with pink triangles. i Correlation between focal deletion number of the 13 genes and percentage of viable tumor cells. j All and clonal neoantigen number generated by two groups. Adenocarcinoma samples were marked with pink triangles. k Clonal TNB value distribution in two groups. l Correlation between clonal TNB and percentage of viable tumor cells